Ian Guider

Ian Guider

Ian Guider is Markets Editor of The Sunday Business Post, and leads the paper’s markets coverage. He previously worked with Newstalk, where he was Business Editor and presenter of the station’s daily business show Breakfast Business. Guider has been a business journalist for more than 15 years, working for a number of Irish and international media groups including the Irish Examiner, the Sunday Tribune and Bloomberg, where he was Banking Correspondent.

Budget 2017: The Brexit-shaped hole in the budget

Budget 2017: The Brexit-shaped hole in the budget

The government’s defence of its limp budget response to Brexit is that its impact is impossible to predict, but it must come up with a plan

Jobs minister heads to Silicon Valley for first US trade mission

Jobs minister heads to Silicon Valley for first US trade mission

Mary Mitchell O'Connor on mission to shore up the country’s international reputation

Budget day left the markets and the rest of us scratching our heads 

Budget day left the markets and the rest of us scratching our heads 

Market Talk

Facebook still routing British ad sales via Ireland

Facebook still routing British ad sales via Ireland

All of the £210 million in turnover booked by British division came from fees from its Irish arm

Market Talk: Quantitative easing party may be over

Market Talk: Quantitative easing party may be over

It looks like the ECB may finally be about to turn off its golden tap of quantitative easing. But what comes next?

A-Z  of Budget 2017

A-Z of Budget 2017

Ian Guider lists the topics likely to take centre stage in what could be Michael Noonan’s final budget speech

Investors tell Trinity Biotech to find a buyer

Investors tell Trinity Biotech to find a buyer

Company shares collapsed 50% after it withdrew key heart attack test

Analysts ramp up pressure on Aryzta over Picard plans

Analysts ramp up pressure on Aryzta over Picard plans

Company bought a 49 per cent stake in Picard for €450 million last year

Cancer drug firm Carrick to begin ‘multi-portfolio’ clinical trials within year

Cancer drug firm Carrick to begin ‘multi-portfolio’ clinical trials within year

Dublin-based firm aiming to fight aggressive forms of cancer has raised $95m from investors

Denis O’Brien’s Digicel dilemma

Denis O’Brien’s Digicel dilemma

Is the time now right for Denis O’Brien to try a float of Digicel, or are the waters still too choppy?

Sean Quinn hastened demise of Anglo, says billionaire Coulson

Sean Quinn hastened demise of Anglo, says billionaire Coulson

Coulson said regulators had not learned from previous insurance failures

Invested: In The Departure Lounge

Invested: In The Departure Lounge

Almost three months on from Brexit, we have yet to witness catastrophe: so what's next?

Market Talk

Market Talk

Eight years on from the guarantee, the banks’ debts remain huge

Will  The Fiscal  Space Become  A  Black  Hole?

Will The Fiscal Space Become A Black Hole?

Since the summer, the tax taken by the state has lagged behind what the Department of Finance had expected

Nama boss: pulling Project Eagle sale ‘a far worse option’

Nama boss: pulling Project Eagle sale ‘a far worse option’

Brendan McDonagh said no one had identified any higher bid for Project Eagle